"Patent linkage" refers to a system or process by which a country links drug marketing approval to the status of the patents corresponding to the originator’s product. This system first originated in the United States. In China, there are many new laws and regulations related to “patent linkage”, the latest of which is the Implementing Measures for a Pharmaceutical Patent Dispute Early Resolution Mechanism (Trial for Implementation) (“Implementation Measures”) that was jointly issued by China National Medical Products Administration and the China National Intellectual Property Administration (CNIPA) on 4 July 2021.
In addition to the Implementation Measures, regulations in China concerning patent linkage include the Measures for the Administrative Ruling of the Early Settlement Mechanism of Drug Patent Disputes and the Provisions on Several Issues Concerning the Application of Law to the Trial of Civil Cases of Patent Disputes Related to Registered Pharmaceutical Products. These regulations have built up the basic framework of China's drug patent linkage system and formed a "Chinese solution" for the early resolution of drug patent disputes.
China also launched a patent information registration platform for marketed drugs, which functions similar to the US "Orange Book".
Source：
https://baijiahao.baidu.com/s?id=1707751024441616844&wfr=spider&for=pc
(Chinese)
http://field.10jqka.com.cn/20210810/c631705428.shtml
(Chinese)